Drugs / YMN-A02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07580261 | Jul 2026 → Jun 2028 expected | hepatocellular carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07610707 | Jul 2026 → Jun 2028 expected | colorectal cancer | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YMN-A02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07580261 ↗ |
| Action | Inhibit | “simultaneous blockade of immune checkpoints and the TGF-β signaling pathway” NCT07580261 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07580261 ↗ |